Literature DB >> 3871178

Optimized conditions for determining activity concentration of alpha-amylase in serum, with 1,4-alpha-D-4-nitrophenylmaltoheptaoside as substrate.

E Rauscher, U Neumann, E Schaich, S von Bülow, A W Wahlefeld.   

Abstract

We describe a method for measuring the catalytic activity of alpha-amylase (EC 3.2.1.1) in serum and urine, by use of a defined substrate: 1,4-alpha, D-4-nitrophenyl maltoheptaoside. We use a phosphate buffer of pH 7.10, containing chloride as activator and alpha-glucosidase (EC 3.2.1.20) as the auxiliary enzyme. After a lag phase of 4 min at 25 degrees C or 30 degrees C, or 3 min at 37 degrees C, the increase of absorption of 4-nitrophenol is measured at 410 nm or 405 nm. The pH value of the assay mixture is a compromise between optimum pH for the alpha-amylase reaction, shortest possible lag phase, and an acceptable absorptivity of 4-nitrophenol. Because the dissociation of 4-nitrophenol depends strongly on pH and temperature, we determined its absorptivity with various combinations of these variables in the assay. Heparin-treated plasma can be used, but not EDTA, fluoride, or citrate. Lipemia, hemoglobin less than or equal to mumol/L, bilirubin less than or equal to 170 mumol/L, glucose less than or equal to 100 mmol/L, and ascorbic acid less than or equal to 1 mmol/L of sample do not interfere in the assay.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871178

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  10 in total

1.  Evaluation of serum iso-amylase in the normal dog using an improved electrophoretic technique.

Authors:  J W Simpson; D L Doxey; G Keay
Journal:  Vet Res Commun       Date:  1989       Impact factor: 2.459

2.  Tumor-associated trypsin inhibitor in patients with chronic pancreatic diseases.

Authors:  M Plebani; D Basso; C Fabris; T Meggiato; G Del Favero; M P Panozzo; P Fogar; D Faggian; C Angonese; A Burlina
Journal:  Klin Wochenschr       Date:  1989-10-17

3.  Oxygen derived free radicals in patients with chronic pancreatic and other digestive diseases.

Authors:  D Basso; M P Panozzo; C Fabris; G del Favero; T Meggiato; P Fogar; A Meani; D Faggian; M Plebani; A Burlina
Journal:  J Clin Pathol       Date:  1990-05       Impact factor: 3.411

4.  The effect of chronic exercise on the rat pancreas.

Authors:  K Minato; Y Shiroya; Y Nakae; T Kondo
Journal:  Int J Pancreatol       Date:  2000-04

5.  Dissociation of cholecystokinin and pancreaticobiliary response to intraduodenal bile acids and cholestyramine in humans.

Authors:  I Koop; S Dorn; H Koop; S Witzleb; C Beglinger; A Schafmayer; R Arnold
Journal:  Dig Dis Sci       Date:  1991-11       Impact factor: 3.199

6.  Acute reflux pancreatitis in rats: a comparison between two experimental models.

Authors:  A Infantino; C Fabris; D Basso; G Del Favero; S Munaretto; M Plebani; M P Panozzo; T Meggiato; A Fassina; M Lise
Journal:  Gastroenterol Jpn       Date:  1992-10

7.  Enzyme activity in bovine cervical mucus during spontaneous and induced estrus.

Authors:  Th Tsiligianni; A Karagiannidis; Ph Saratsis; P Brikas
Journal:  Can J Vet Res       Date:  2003-07       Impact factor: 1.310

8.  Sensitivity and specificity of an abbreviated (13)C-mixed triglyceride breath test for measurement of pancreatic exocrine function.

Authors:  Jutta Keller; Viola Meier; Kristina U Wolfram; Ulrich Rosien; Peter Layer
Journal:  United European Gastroenterol J       Date:  2014-08       Impact factor: 4.623

9.  Induction of the fed pattern of human exocrine pancreatic secretion by nutrients: role of cholecystokinin and neurotensin.

Authors:  M Katschinski; C Dippel; M Reinshagen; J Schirra; R Arnold; R Nustede; C Beglinger; G Adler
Journal:  Clin Investig       Date:  1992-10

10.  In Vitro Anti-Echinococcal and Metabolic Effects of Metformin Involve Activation of AMP-Activated Protein Kinase in Larval Stages of Echinococcus granulosus.

Authors:  Julia A Loos; Andrea C Cumino
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.